Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortüm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial S. Nooka AK, et al. Among authors: sborov d. Cancer. 2023 Dec 1;129(23):3746-3760. doi: 10.1002/cncr.34987. Epub 2023 Aug 25. Cancer. 2023. PMID: 37622738 Free PMC article.
Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. Canella A, et al. Oncotarget. 2023 Sep 25;14:837-838. doi: 10.18632/oncotarget.28515. Oncotarget. 2023. PMID: 37747363 Free PMC article. No abstract available.
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. Canella A, et al. Oncotarget. 2015 Oct 13;6(31):31134-50. doi: 10.18632/oncotarget.5290. Oncotarget. 2015. PMID: 26429859 Free PMC article.
IFITM3 regulates fibrinogen endocytosis and platelet reactivity in nonviral sepsis.
Campbell RA, Manne BK, Banerjee M, Middleton EA, Ajanel A, Schwertz H, Denorme F, Stubben C, Montenont E, Saperstein S, Page L, Tolley ND, Lim DL, Brown SM, Grissom CK, Sborov DW, Krishnan A, Rondina MT. Campbell RA, et al. Among authors: sborov dw. J Clin Invest. 2022 Dec 1;132(23):e153014. doi: 10.1172/JCI153014. J Clin Invest. 2022. PMID: 36194487 Free PMC article.
How I manage patients with acquired haemophilia A.
Sborov DW, Rodgers GM. Sborov DW, et al. Br J Haematol. 2013 Apr;161(2):157-65. doi: 10.1111/bjh.12228. Epub 2013 Feb 4. Br J Haematol. 2013. PMID: 23373521 Free article. Review.
Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant.
Cho YK, Irby DJ, Li J, Sborov DW, Mould DR, Badawi M, Dauki A, Lamprecht M, Rosko AE, Fernandez S, Hade EM, Hofmeister CC, Poi M, Phelps MA. Cho YK, et al. CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):748-758. doi: 10.1002/psp4.12345. Epub 2018 Oct 20. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 30343510 Free PMC article.
Targeted therapy in sarcomas other than GIST tumors.
Sborov D, Chen JL. Sborov D, et al. J Surg Oncol. 2015 Apr;111(5):632-40. doi: 10.1002/jso.23802. Epub 2014 Oct 20. J Surg Oncol. 2015. PMID: 25330750 Free PMC article. Review.
106 results